Side Step-Wise Development: Sponsors Aren’t Using FDA’s Preferred Approach To Biosimilars

Rather than conduct most analytical characterization and non-clinical studies first, the hallmark of the US FDA approach, biosimilar sponsors are often initiating clinical trials about the same time.